Michal Zimmermann

机构：Zimmerman Associates (United States), Telesta Therapeutics (Canada), AstraZeneca (Canada), St. Laurent Institute · ORCID：0000-0002-9955-1675

发表论文 103 篇 · 总被引 6992 次 · h-index 23

代表论文

• The Discoveryof RP-2119: A Potent, Selective, andOrally Bioavailable Polθ ATPase Inhibitor (2025 · Journal of Medicinal Chemistry · 被引 10)
• The PLK4 inhibitor RP-1664 demonstrates potent single-agent efficacy in neuroblastoma models through a dual mechanism of sensitivity (2025 · Research Square · 被引 1)
• Structure and mechanism of inhibition of lysine demethylase 2A (KDM2A) by compound 183c (2026 · Communications Chemistry)
• Supplementary Table S3 from Camonsertib, an ATRi, in Combination with Low-Dose Gemcitabine in Solid Tumors with DNA Damage Response Aberrations: Preclinical and Phase Ib Results (2026)
• Supplementary Table S6 from Camonsertib, an ATRi, in Combination with Low-Dose Gemcitabine in Solid Tumors with DNA Damage Response Aberrations: Preclinical and Phase Ib Results (2026)
• Table 3 from Camonsertib, an ATRi, in Combination with Low-Dose Gemcitabine in Solid Tumors with DNA Damage Response Aberrations: Preclinical and Phase Ib Results (2026)